Martín Angel· @Martin_AngelMD · X·· 14 hours agoScore70
Body
Presidential symposium 1️⃣!!
DeLLphi-305 study:
Tarlatamab + durva significantly improved ✅ OS, PFS, and ORR ‼️ in 1LM ES-SCLC @myESMO #ESMO26 a 🆕 standard of care!
51 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
LBA3matched by Presidential Symposium I
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgSource: Martín Angel · x.com